This score calculates overall vulnerability severity from 0 to 10 and is based on the Common Vulnerability Scoring System (CVSS). Attack vector: More severe the more the remote (logically and ...

This score calculates overall vulnerability severity from 0 to 10 and is based on the Common Vulnerability Scoring System (CVSS). Attack Vector: This metric reflects the context by which vulnerability ...

15/10 Recursion Pharmaceuticals, Inc. annonce que Sanofi prend une option sur un potentiel candidat en immunologie, premier de sa catégorie, issu de leur collaboration CI 15/10 Recursion fixe le prix ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Recursion (Nasdaq: RXRX) announced it will provide business updates and report its second quarter 2026 financial results on Wednesday, August 5, 2026, before U.S. financial markets open. RXRX had 2 ...

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

Recursion Pharmaceuticals operates as a TechBio company, using its proprietary Recursion OS to automate biological experiments and analyze them with artificial intelligence. The company generates vast ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

- Recursion RXRX--maintains 2026 cash expenses under $390M, extending runway to early 2028 with $665M in cash. - Five wholly-owned clinical programs will deliver key data in 12-18 months, including ...